% 0期刊文章%玛丽亚·A·罗卡%一个Paola Valsasina Mohammad Aboulwafa % %一个保罗Preziosa %弗雷德里克Barkhof %雨果Vrenken Chiara Zecca %克劳迪奥·米兰球迷% %一个Xavier好吃的亚历克斯·罗维拉% %一个休·卡尼% Olga Ciccarelli %露西Matthews %杰奎琳宫殿%一个安东尼奥Gallo % Alvino Bisecco % Achim Gass %菲利普会怎样%一个芭芭拉Bellenberg Carsten卢卡斯% %吉安卡洛Comi %马西莫菲利皮主持% T纵向评估颈脊髓萎缩的临床表型女士:一项多中心研究(S2.002) % D J神经病学2017% % P S2.002 X % V % 88% N 16补充目的:跟踪的纵向演化颈脊髓萎缩在多发性硬化症(MS)的主要疾病患者临床表型及其临床意义,通过分析一个大型、多中心数据集获得9个欧洲网站。首页背景:女士的特点是严重的颈脊髓萎缩,这可能是临床相关,有助于解释残疾进展。设计/方法:基线3 d t1颈线扫描获得从167名健康对照组(HC)和421 MS患者(36临床孤立综合征(CIS), 202年复发缓和(名RRMS)女士,96年二次进步(spm)女士,45良性(BMS)女士和42个主要进步女士[专业])。从157年的后续扫描对象(49 HC和108 MS患者,平均随访时间= 1.1年,范围= 0.5 - -2.1年)。Whole-cervical线横截面积(CSA)是使用一个活跃的表面方法评估。基线CSA及其纵向变化HC和MS患者之间相比,临床恶化和稳定的患者,使用方差分析模型和在疾病临床表型(调整年龄、性别和地点)和配对t检验。结果:基线CSA在MS患者和HC降低(p < 0.001),项目组合管理系统对HC和CIS (p < 0.001),名RRMS vs CIS (p = 0.001),和spm和百时美施贵宝(p < 0.001)和名RRMS (p < 0.001)。纵向线CSA变化在HC + 0.01% (p = 0.9)和女士−1.1% (p = 0.001),与大量的时间x集团交互(p = 0.04)。临床表型分析分别时,明显的脊髓组织损失被发现在名RRMS (CSA改变=−1.5%,p = 0.001)和项目组合管理系统(CSA改变=−2.0%,p = 0.05)。临床医学患者恶化发展脊髓萎缩明显高于临床稳定的女士(CSA改变=−−2.2% 0.7%,p时间x集团互动= 0.03)。结论:除了CIS,重要的颈脊髓萎缩表型女士被发现在所有。一年期绳萎缩是临床相关的女士和发展在不同的速率主要表型,在项目组合管理系统和名RRMS患者更严重。研究支持:穆罕默德Aboulwafa一直支持的ECTRIMS-MAGNIMS MRIDisclosure奖学金:罗卡博士已经收到个人赔偿的活动与诺华、Idec, Teva神经科学和Genzyme演讲者。 Dr. Aboulwafa has nothing to disclose. Dr. Valsasina has nothing to disclose. Dr. Preziosa has received personal compensation for activities with Biogen Idec, Novartis and ExceMED as a speaker. Dr. Barkhof has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Sanofi Genzyme, Janssen Research, Merck Serono, Novartis, Roche, Synthon BV, and Teva Neuroscience as a consultant or a speaker. Dr. Vrenken has received research support from EMDSerono. Dr. Gobbi has nothing to disclose. Dr. Zecca has nothing to disclose. Dr. Rovira has received personal compensation for activities with Genzyme, Novartis, Biogen, Bracco, and Teva. Dr. Montalban has received personal compensation for activities with Almirall, Bayer, Biogen, Celgene, Sanofi Genzyme, Merck, Novartis, Roche, and Teva Pharmaceutical. Dr. Kearney has nothing to disclose. Dr. Ciccarelli has received personal compensation for activities with Novartis, Biogen and GE as a consultant. Dr. Matthews has nothing to disclose. Dr. Palace has received personal compensation for activities with Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma, Alexion and Bayer Schering as an advisor. Dr. Gallo has received personal compensation for activities with Biogen, Sanofi-Aventis, Merck Serono, Genzyme, Teva, Bayer-Schering and Novartis as a speaker along with travel grants. Dr. Bisecco has nothing to disclose. Dr. Gass has received personal compensation for activities with Biogen Idec and Novartis. Dr. Eisele has nothing to disclose. Dr. Lukas has nothing to disclose. Dr. Bellenberg has nothing to disclose. Prof. Comi has received personal compensation for activities with Novartis, Teva Pharmaceutical Ind. Ltd, Sanofi, Genzyme, Merck Serono, Bayer, Actelion Sano as a speaker, consultant or participating on an advisory board. Dr. Filippi has received personal compensation for activities with Biogen Idec, Excemed, Novartis, and Teva as a consultant and/or speaker. %U